Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DUAL VII: IDegLira vs Basal-Bolus in T2DM
NCT02420262Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Jul 2015
- Primary completion
- Oct 2016
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 12
01
Overview
A Phase 3 trial of insulin degludec + liraglutide in type 2 diabetes mellitus (T2DM), sponsored by Novo Nordisk. Started Jul 2015; status: completed.
02
Drugs
insulin degludec + liraglutide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02420262.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02420262.